Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx UK II
OPTIRPE65 is an adeno-associated virus (AAV) vector gene therapy that carries the RPE65 gene. It is studied in Leber congenital amaurosis, a hereditary retinal disease, and other hereditary eye and retinal diseases.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02946879 | N/A | Leber Congenital Amaurosis (LCA) | Completed | MGTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Eye DiseasesEye Diseases, HereditaryLeber Congenital Amaurosis (LCA)Retinal Diseases
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGTX page.
See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGTX catalysts and pipeline →